Transient Pulmonary Infiltrates: A Hypersensitivity Reaction to Paclitaxel

Letters15 January 1996Transient Pulmonary Infiltrates: A Hypersensitivity Reaction to PaclitaxelRamesh K Ramanathan, MD, Chandra P. Belani, MD, and Vundyala V. Reddy, MDRamesh K Ramanathan, MDUniversity of Pittsburgh Medical Center; Pittsburgh, PA 15213Macon, GA 31201Search for more papers by this author, Chandra P. Belani, MDUniversity of Pittsburgh Medical Center; Pittsburgh, PA 15213Macon, GA 31201Search for more papers by this author, and Vundyala V. Reddy, MDUniversity of Pittsburgh Medical Center; Pittsburgh, PA 15213Macon, GA 31201Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-124-2-199601150-00030 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Pulmonary infiltrates caused by a hypersensitivity reaction are not a known side effect of paclitaxel [1-3]. We describe two patients with transient pulmonary infiltrates seen after they received treatment with paclitaxel in combination with carboplatin. We believe that these transient infiltrates probably resulted from a hypersensitivity reaction caused by paclitaxel or the cremophor EL vehicle used in the formulation. Fever and peripheral eosinophilia did not accompany the infiltrates.The first patient was a 66-year-old woman who began receiving carboplatin and paclitaxel for metastatic non-small-cell lung cancer. Paclitaxel was given at 175 mg/m2 body surface area for 24 ...References1. Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC. Clinical toxicities encountered with paclitaxel (Taxol®). Semin Oncol. 1993; 20(4 Suppl 3):1-15. Google Scholar2. Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, et al. Hypersensitivity reactions to Taxol. J Clin Oncol. 1990; 8:1263-8. Google Scholar3. “Package insert. Taxol (paclitaxel) for injection concentrate. Princeton, NJ: Mead Johnson Oncology Products; revised April 1994.” Google Scholar Author, Article, and Disclosure InformationAffiliations: University of Pittsburgh Medical Center; Pittsburgh, PA 15213Macon, GA 31201 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByPneumonia induced by eribulin mesylate in a patient with recurrent breast cancerDiagnosis and management of drug-associated interstitial lung diseaseIatrogenic lung diseasePhase II Trial of Docetaxel and Vinorelbine in Patients With Advanced Non–Small-Cell Lung CancerPhase I trial of docetaxel and vinorelbine in patients with advanced nonsmall cell lung carcinomaSevere pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinomaPaclitaxel-Induced Acute Bilateral PneumonitisDocetaxel and interstitial pulmonary injuryPaclitaxel 15 January 1996Volume 124, Issue 2Page: 278KeywordsChemotherapyEosinophiliaFeversHemorrhageHypersensitivityLung and intrathoracic tumorsOxygenPneumonitisPulmonary diseasesThorax Issue Published: 15 January 1996 CopyrightCopyright © 1996 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...